Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding

PHASE3CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2008

Conditions
Esophageal VaricesPortal HypertensionGastric VaricesEsophageal Bleeding
Interventions
DRUG

Sanvar® (vapreotide)

Trial Locations (19)

10021

Weill Medical College of Cornell University, New York

10032

Columbia University Medical Center, New York

21205

Johns Hopkins Hospital & School of Medicine, Div. of Gastroenterology & Hepatology, Baltimore

23298

Virginia Commonwealth University MCV Campus West Hospital, Richmond

28801

Mission Hospitals, Inc., Asheville

29425

Medical University of South Carolina, Charleston

32224

Mayo Clinic, Jacksonville

36116

Alabama Liver & Digestive Specialists, Montgomery

40536

University of Kentucky Medical Center, Lexington

46202

Indiana University School of Medicine, Indianapolis

60611

Northwestern University, The Feinberg School of Medicine, Chicago

63110

Washington University School of Medicine, St Louis

78229

CHRISTUS Santa Rosa Medical Center, San Antonio

80262

University of Colorado Health Sciences Center, Denver

85054

Mayo Clinic, Scottsdale

35294-0005

UAB Liver Center, Birmingham

92103-8707

University of California at San Diego, San Diego

06520

Yale University School of Medicine, New Haven

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Debiovision

INDUSTRY

NCT00331188 - Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding | Biotech Hunter | Biotech Hunter